New combination therapy eradicates prostate cancer in vivo
In their study, published in the journal Proceedings of the National Academy of Sciences, prostate cancer growth in mice with functioning immune systems was inhibited by sensitizing the cancer cells with the drug Sabutoclax (BI-97C1) and using UTMD technology to deliver a viral gene therapy that expresses the genemda-7/IL-24. This powerful new approach to treating prostate cancer builds upon prior studies by principle investigator Paul B. Fisher, M.P.H., Ph.D., Thelma Newmeyer Corman Endowed Chair in Oncology Research at VCU Massey (photo on left). Fisher is professor and chair of the Department of Human and Molecular Genetics in the VCU School of Medicine, and director of the VCU Institute of Molecular Medicine.
New biomarker predicts breast cancer relapse
Researchers from Virginia Commonwealth University Massey Cancer Center have discovered a new biomarker related to the body’s immune system that can predict a breast cancer patient’s risk of cancer recurrence. This breakthrough may lead to new genetic testing that further personalizes breast cancer care.
Translational research: from bench to bedside
Massey’s science-driven translational research – moving scientific discoveries from the laboratory into real-world patient applications – is one of the many reasons the National Cancer Institute recently awarded Massey a five-year renewal as one of only two NCI-designated Cancer Centers in Virginia. Often described as “bench-to-bedside” research, translational research involves several stages, including clinical trials, where consenting patients are given drugs, surgical procedures, devices or other interventions to treat cancer and are then closely monitored to determine side effects, effectiveness and other key findings.
Physician-researcher receives 2012 Alliance Research Grant
VCU Massey Cancer Center hematologist-oncologist Beata Holkova, M.D., was recently awarded an Alliance Research Grant to support her work involving drug combinations to battle B-cell lymphomas. The grant was presented at this year’s Alliance Group Meeting in Chicago, Illinois. Holkova is a Harrison Endowed Scholar and member of the Developmental Therapeutics research program at VCU Massey Cancer Center and assistant professor of hematology-oncology and internal medicine at the VCU School of Medicine.
Viagra drug trio improves effectiveness of cancer treatment while protecting the heart
A new drug combination featuring the widely-known impotence drug Viagra has been found to improve the effectiveness of cancer treatment while protecting the heart from harm caused by a popular form of chemotherapy. With nearly half of all cancer survivors dying from other conditions than cancer, most notably cardiovascular disease, this new treatment is not only innovative but necessary.